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High body mass index (BMI) and use of hormone replacement therapy (HRT) increase the risk of postmenopausal breast cancer. It
has been shown that BMI modifies the effect of HRT, as its influence is most pronounced in lean women. We investigated the
influence of BMI and HRT on prognosis in 2640 postmenopausal women diagnosed with breast cancer in Sweden in 1993–1995,
taking into account HRT and mammography before diagnosis. Logistic and Cox regression were used. In non-users of HRT, obese
women (BMI 430) compared with normal weight women (BMI o25) had a similar prognosis (hazard ratio (HR) 1.1, 95%
confidence interval (CI) 0.8–1.6), despite larger tumours found in obese women. Obese HRT users had less favourable tumour
characteristics and poorer prognosis compared with normal weight women (HR 3.7, 95% CI 1.9–7.2). The influence of BMI on breast
cancer prognosis was similar whether diagnosed by mammographic screening or not. We found a similar prognosis of
postmenopausal breast cancer-specific death regardless of BMI in non-users of HRT, but among HRT users obesity was associated
with a poorer breast cancer prognosis.
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Obesity has repeatedly been associated with breast tumours of
larger size, lymph node positivity, and poor prognosis (Chlebowski
et al, 2002; Dal Maso et al, 2008), although some studies have
produced contrasting findings (Dignam et al, 2003; Berclaz et al,
2004). However, many studies lack information on the use of
hormone replacement therapy (HRT) and mammography exam-
inations before diagnosis. Use of HRT interacts, or rather
competes, with obesity on breast cancer risk among postmeno-
pausal women, probably by sharing hormonal carcinogenic
pathways (van den Brandt et al, 2000; Morimoto et al, 2002).
The HRT effect on risk is most pronounced in lean postmeno-
pausal women, in whom the endogenous production of oestrogen
is the lowest. Obese women might benefit more from mammo-
graphic screening than normal weight women because of larger
breasts, more difficult to palpate, and a lower mammographic
breast density, and thereby a higher sensitivity of the mammo-
graphy (Porter et al, 2006; Kerlikowske et al, 2008). Therefore, not
taking HRT use and mammographic screening pattern into
consideration could create spurious relationships between prog-
nosis and obesity. Obesity is linked to an increased all-cause
mortality (Lahmann et al, 2002; Adams et al, 2006), which means
that using all-cause mortality as the outcome might obscure the
association between obesity and breast cancer death. We therefore
studied the influence of obesity on tumour characteristics and
cause-specific mortality in postmenopausal breast cancer patients,
taking into account HRT use before diagnosis and mode of
detection.
MATERIALS AND METHODS
We used information from all cases initially participating in a
population-based case-control study conducted in Sweden between
October 1993 and March 1995. Detailed information on data
collection is given elsewhere (Magnusson et al, 1999). Briefly, all
women born in Sweden aged 50–74 years at first diagnosis of
invasive breast cancer were eligible. The investigation was
approved by all the seven regional ethical review boards in
Sweden, and informed consent was obtained from each partici-
pant. The mean interval from diagnosis to answering the mailed
questionnaire was 4.3 months.
Out of 3979 women with a first diagnosis of breast cancer, 3345
women (84%) participated in the study. Menopause was defined as
the age at last menstrual period or age at bilateral oophorectomy, if
1 year or more before data collection. Exclusions were made
because of earlier cancer (150 cases), noninvasive breast cancer
according to patient record not reported from the regional cancer
registry (58), diagnosed outside study period (19), lack of
permission to access patient record information (58), other cancer
than breast cancer (1), being premenopausal (198) as well as being
below age 55 years with unknown age at menopause (possibility of
being premenopausal, 202 cases), missing age at first birth (5), and
missing height or recent weight (14). Thus, 2640 cases remained
for analysis. Data on possible breast cancer risk factors including
information on use of HRT were collected through a mailed
questionnaire.
We collected information on mode of detection (screening or
not), primary treatment (surgery, chemotherapy, radiotherapy,
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yand endocrine therapy), and tumour characteristics (tumour size,
lymph node involvement, grade, and oestrogen and progesterone
receptor status) from patient records primarily from surgical and
oncological units throughout Sweden. Information on grade was
not in routine clinical use in Sweden at the time of the study, and is
consequently missing in 33% of the cases. From breast radiology
units, we collected information on date and reason for the
mammographies (screening or referral) carried out before
diagnosis.
We used the Swedish National Registration Number, unique to
each citizen, to collect information on emigrations from the
Swedish National Population Register, and to obtain information
on date and cause of death until December 31 2003 from the
Swedish Cause of Death Register. The latter register covers all
residents, and has been shown to correctly classify 98% of deaths
in breast cancer patients (Nystrom et al, 1995).
According to the World Health Organization (WHO), BMI
(body mass index 1 year before answering the questionnaire,
kgm
 2) was classified into underweight (o18.5), normal weight
(18.5–25), overweight (25–30), and obese (430). As only 34
women were underweight, they were merged with the normal
weight group. Recent mammography was defined as the mammo-
graphy within 2 years and 2 months before diagnosis (yes/no), to
cover the normal 2-year interval of mammographic screening and
2 months delay. Detection by screening was defined as diagnosis
by the official screening programme or by other health checks
without symptoms.
HRT was classified into ever use of (a) oestrogen in combination
with progestin (oestrogen-progestin), (b) oestrogen alone, or (c)
never use of HRT. Current oestrogen–progestin use was defined as
the last use within 6 months before diagnosis. Progestin alone was
largely classified as past use more than 10 years before diagnosis,
and therefore not analysed, but excluded from never use of HRT.
Oral estriol and local oestrogen treatment was not defined as HRT.
Grade was collected from pathological reports, and was
classified according to the Nottingham histological grade or the
Bloom-Richardson scale (Bloom and Richardson, 1957; Elston and
Ellis, 1991). Oestrogen- or progesterone-positive was defined as
X0.05fmol receptor per microgram DNA or X10fmol receptor
per miligram protein.
Statistical analyses
Means and frequencies of various background factors according to
BMI groups were calculated, and t-test (for means) and w
2-tests
(for frequencies) were carried out to detect differences between
obese and normal weight women.
We used frequencies with w
2-tests, as well as polytomous
multiple logistic regression to estimate odds ratios (OR) with 95%
confidence intervals (CIs) for the associations between BMI groups
and tumour characteristics, with one class of each tumour
characteristic as control group and the other(s) as outcome(s).
Age at diagnosis, parity, at first birth, menopause, current alcohol
intake, socioeconomic status, and current smoking status were
evaluated separately as potential confounders of the associations of
interest, and were included in the final models if they affected any
of the estimates more than 10%. In addition, we carried out the
same analyses stratified by use of HRT.
We used the Kaplan–Meier method with log-rank test for
assessing breast cancer-specific mortality distributions in relation
to BMI among all women and stratified for HRT use. We estimated
breast cancer-specific mortality rates, and used the Cox propor-
tional hazards model to compare the HRs of such deaths between
BMI categories, among all women and in strata by HRT use and by
detection by screening. Heterogeneity of the BMI effect by HRT
use and by detection by screening was tested using Wald w
2-test.
Potential confounders were tested by inclusion in an age-stratified
Cox model. Tumour characteristics (tumour size and lymph node
involvement) and treatment are intermediates between BMI
exposure and breast cancer survival, and were thus included in
Cox models to assess the extent to which they could explain the
observed associations.
RESULTS
Obese, compared with normal weight women, were older at
diagnosis, drank less alcohol, were of lower socioeconomic status,
were less often HRT users or current smokers, and were more
often diagnosed by mammographic screening (Table 1). There
were no differences between BMI groups regarding parity, age at
first birth, number of children, or age at menopause. The
proportion of women with a recent mammography (within 2 years
and 2 months before diagnosis) did not differ between normal
weight and obese women.
Compared with normal weight women, obese women more often
had large tumours, lymph node positivity, and progesterone
receptor-positive tumours (Table 2). We found no difference in
grade or oestrogen receptor status between normal weight and
obese women. Among never users of HRT there was a slight
attenuation of the associations between obesity and both large
tumour size and lymph node involvement (Table 2). On the other
hand, the association between obesity and progesterone receptor
positive-tumours was strengthened. In contrast, obese women ever
using oestrogen–progestin therapy seemed to have tumours with
less favourable prognostic characteristics. Obese compared with
Table 1 Baseline characteristics of 2640 postmenopausal Swedish
women diagnosed with breast cancer in 1993–1995, by body mass index
BMI
o25 25–30 430 P-value
No. of cases 1267 997 376
Mean
Age at diagnosis (years) 62.4 64.0 64.7 o0.0001
Parity 1.8 1.9 1.8 0.34
Age at first birth (years) 25.5 25.3 25.3 0.68
Age at menopause
a (years) 50.5 50.7 50.4 0.88
Current alcohol intake, gday
 1 2.9 2.3 1.7 o0.0001
Frequency (%)
High socioeconomic status
b 54 47 39 o0.0001
Ever HRT
Ever oestrogen alone 14 10 7 0.0005
Ever oestrogen–progestin 30 15 12 o0.0001
Current smoker 30 18 13 o0.0001
Recent mammography
c 65 60 64 0.64
Detection by screening 57 63 65 0.012
Primary treatment
Surgery 99 100 99 0.86
Chemotherapy 8 9 11 0.15
Antioestrogenic therapy 54 51 57 0.30
Radiotherapy 64 62 63 0.96
Deceased at end of follow-up 24 24 35 0.0003
Cause of death
Breast cancer 15 15 21 0.0008
Other cause 9 9 14 0.0014
BMI¼body mass index (kgm
 2); HRT¼hormone replacement therapy. P-value:
two sided t-test for means and w
2-test for the frequencies comparing BMI 430 vs
BMI o25.
aAmong women with a natural menopause.
bHigh level includes medium-
and high-level white collar workers.
cMammography within 2 years and 2 months
before diagnosis.
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tumours, and there was a strong association with lymph node
involvement, whereas there was no association with progesterone
receptor status (Table 2). Women with oestrogen alone use were
few, but as the patterns of tumour characteristics over BMI
categories were similar compared with women with no HRT use
(data not shown), oestrogen alone use was not further analysed.
Among obese women, 35% died during the follow-up (median
follow-up 9.5 years, range 8.8–10.2), whereas 24% of both
overweight and normal weight women died (Table 1). Death
because of breast cancer was more common than death because of
other causes regardless of BMI. Breast cancer-specific survival was
poorer among obese women compared with normal and over-
weight women (Figure 1A). BMI did not influence survival in those
Table 2 Distribution of tumour characteristics by body mass index, and adjusted odds ratios for tumour characteristics in relation to body mass index, by
the use of HRT: the Swedish Breast Cancer Study 1993–2003
BMI Adjusted OR
Tumour characteristics o25 25–30 430 P-value* 25–30 95% CI 430 95% CI
All women
Tumour size (cm)
p2 919 (73) 702 (71) 241 (64)
42 333 (27) 287 (29) 133 (36) 0.0014 1.2 1.0, 1.4 1.6 1.2, 2.0
Lymph node positivity
No 854 (70) 651 (68) 229 (64)
Yes 370 (30) 313 (32) 127 (36) 0.046 1.1 0.9, 1.4 1.3 1.0, 1.7
Grade
1 129(16) 104 (15) 37 (15)
2 359 (43) 272 (40) 104 (41) 0.9 0.6, 1.2 0.9 0.6, 1.4
3 339 (41) 309 (45) 110 (44) 0.29 1.1 0.8, 1.5 1.1 0.7, 1.6
Oestrogen receptor
Positive 710 (78) 540 (77) 229 (81)
Negative 199 (22) 158 (23) 53 (19) 0.44 1.1 0.9, 1.4 0.9 0.6, 1.3
Progesterone receptor
Positive 570 (64) 468 (68) 198 (71)
Negative 316 (36) 220 (32) 82 (29) 0.029 0.9 0.7, 1.1 0.8 0.6, 1.0
Never hormone replacement therapy
Tumour size (cm)
p2 531 (72) 519 (71) 186 (64)
42 207 (28) 213 (29) 103 (36) 0.033 1.1 0.9, 1.4 1.4 1.1, 1.9
Lymph node positivity
No 496 (69) 483 (68) 179 (66)
Yes 222 (31) 229 (32) 93 (34) 0.33 1.1 0.9, 1.3 1.2 0.9, 1.6
Grade
1 67 (13) 65 (13) 31 (16)
2 229 (46) 207 (41) 83 (43) 0.90 0.8 0.6, 1.3 0.7 0.4, 1.1
3 204 (41) 232 (46) 80 (41) 1.1 0.8, 1.7 0.8 0.5, 1.3
Oestrogen receptor
Positive 421 (79) 395 (77) 174 (81)
Negative 113 (21) 116 (23) 41 (19) 0.73 1.1 0.8, 1.5 0.9 0.6, 1.3
Progesterone receptor
Positive 316 (61) 345 (69) 150 (70)
Negative 204 (39) 158 (31) 63 (30) 0.0036 0.7 0.5, 0.9 0.6 0.4, 0.9
Ever oestrogen–progestin therapy
Tumour size (cm)
p2 278 (76) 110 (73) 28 (65)
42 90 (24) 41 (27) 15 (35) 0.15 1.2 0.8, 1.9 1.9 0.9, 3.8
Lymph node positivity
No 260 (71) 97 (66) 21 (50)
Yes 104 (29) 51 (35) 21 (50) 0.0051 1.3 0.9, 2.0 2.7 1.4, 5.2
Grade
1 54 (23) 26 (24) 3 (10)
2 92 (40) 36 (34) 10 (34) 0.7 0.4, 1.4 2.0 0.5, 7.7
3 86 (37) 45 (42) 16 (55) 0.084 1.3 0.7, 2.4 3.4 0.9, 12.7
Oestrogen receptor
Positive 207 (78) 86 (79) 28 (78)
Negative 60 (22) 23 (21) 8 (22) 0.86 1.1 0.6, 1.9 1.2 0.5, 3.0
Progesterone receptor
Positive 187 (71) 73 (68) 24 (67)
Negative 75 (29) 34 (32) 12 (33) 0.45 1.3 0.8, 2.2 1.7 0.8, 3.7
BMI¼body mass index (kgm
 2); CI¼confidence interval; HRT¼hormone replacement therapy; OR¼odds ratio. *P-value: Two-sided Mantel–Haenszel w
2 for the distribution
between groups.OR adjusted for age at diagnosis (5-year categories), parity (0, 1, 2, 3, and 43), current smoking (yes/no), and age at menopause (o45, 45–49, 50–54, and
X55 years).
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Figure 1 Kaplan–Meier curve of breast cancer-specific survival by body mass index. The Swedish Breast Cancer Study 1993–2003. (A) All women. (B)
Never use of HRT. (C) Ever use of estrogen–progestin.
Table 3 Breast cancer-specific mortality in relation to body mass index before diagnosis, by the use of HRT or by detection mode: the Swedish Breast
Cancer Study 1993–2003
Breast cancer deaths/exposed Breast cancer mortality rate
a HR
b 95% CI HR
c 95% CI
All women
BMI
o25 162/1090 1.8 1.0 Ref. 1.0 Ref.
25–30 126/873 1.7 1.0 0.8, 1.2 0.9 0.7, 1.2
430 66/322 2.6 1.4 1.1, 1.9 1.2 0.9, 1.6
Never hormone replacement therapy
BMI
o25 108/628 2.1 1.0 Ref. 1.0 Ref.
25–30 99/645 1.9 0.9 0.7, 1.2 0.8 0.6, 1.1
430 45/243 2.3 1.1 0.8, 1.6 0.9 0.6, 1.3
Ever oestrogen–progestin therapy
BMI
o25 36/329 1.2 1.0 Ref. 1.0 Ref.
25–30 10/130 0.9 0.8 0.4, 1.6 1.0 0.5, 2.1
430 13/40 4.3 3.7 1.9, 7.2 2.3 1.1, 5.2
Detected by mammographic screening
BMI
o25 56/612 1.0 1.0 Ref. 1.0 Ref.
25–30 52/548 1.1 1.0 0.7, 1.5 0.9 0.6, 1.4
430 29/209 1.7 1.5 0.9, 2.3 1.0 0.6, 1.6
Not detected by mammographic screening
BMI
o25 104/466 2.8 1.0 Ref. 1.0 Ref.
25–30 74/321 2.9 1.1 0.8, 1.5 0.9 0.7, 1.3
430 36/112 4.6 1.6 1.1, 2.4 1.4 0.9, 2.1
BMI¼body mass index (kgm
 2); CI¼confidence interval; HR¼hazard ratio; HRT¼hormone replacement therapy.
aBreast cancer deaths per 100 person-years.
bAdjusted for
age at diagnosis in 5-year categories, and current alcohol intake (0, 0–4.9, 5–9.9, and X10gday
 1).
cAdjusted for age at diagnosis, current alcohol intake (0, 0–4.9, 5–9.9, and
X10gday
 1), tumour size (p2, 42cm), and lymph node positivity (no, yes).
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oestrogen–progestin users, obese women had a poorer survival
(Figure 1C).
Overall, obese compared with normal weight women had an
increased risk of breast cancer death (HR 1.4, 95% CI 1.1–1.9;
Table 3). When we stratified by the use of HRT, we found no
association between BMI and survival among never HRT users
(HR 1.1, 95% CI 0.8–1.6; Table 3), whereas this association was
clearly evident among oestrogen–progestin users when comparing
obese with normal weight women (HR 3.7, 95% CI 1.9–7.2). In
these analyses, evidence of heterogeneity was found for use of HRT
(P¼0.0029). On the other hand, the influence of BMI on survival
was similar whether diagnosed by mammography screening or not
(P¼0.98).
Adding tumour size and lymph node positivity to the models
seemed to explain part of the increased risk of death for obese
women (Table 3), but obese women ever using oestrogen–
progestin still had twice the risk of dying of breast cancer
compared with normal weight women (HR 2.3, 95% CI 1.1–5.2;
Table 3). Primary treatments of the tumour were not related to
BMI (Table 1), and, as expected, did not influence the survival
estimates (data not shown). Among ever oestrogen–progestin
users, 85% of normal weight women and 63% of obese women
were current users. When the analysis was restricted to current
oestrogen–progestin users, the results of a poorer survival among
obese women were similar and significant (data not shown).
DISCUSSION
We found that among women not using HRT, obese compared
with normal weight women more often had large and progesterone
receptor-positive tumours, but similar breast cancer-specific
survival. On the other hand, obese women using oestrogen–
progestin had worse tumour characteristics and prognosis
compared with normal weight women.
Our findings of modest associations between obesity and poor
tumour characteristics and no association with breast cancer-
specific survival in never users of HRT contradict most earlier
studies (Chlebowski et al, 2002; Dal Maso et al, 2008). Use of HRT
became increasingly popular during the 1990s, but dropped
substantially after the report of adverse effects from the Women’s
Health Initiative. Studies conducted on populations diagnosed
with breast cancer before 2002 often have a large proportion of
current HRT users. As indicated by our data, not taking HRT use
into consideration could introduce spurious associations when
analysing the influence of BMI on prognosis. However, two large
and well-designed studies have found similar breast cancer
survival regardless of BMI without taking HRT use into
consideration (Dignam et al, 2003; Berclaz et al, 2004).
Whether use of HRT before diagnosis is linked to a better breast
cancer prognosis is not clear. Most observational studies indicate
such an association, whereas the Women’s Health Study rando-
mized trial found HRT oestrogen–progestin use to be associated
with larger and lymph node-positive tumours (Antoine et al,
2004). If HRT is linked to less aggressive tumours, our finding of a
poorer survival among obese women only among HRT users could
be explained as follows: the beneficial prognostic effect seen by
HRT in most observational studies is confined to lean women, in
whom the HRT effect is most pronounced. This beneficial effect of
HRT is not seen in obese women.
The aim of studying factors that influence survival is to identify
groups with a particularly bad prognosis, with the ultimate goal of
individualising cancer treatment. Many studies of obesity and breast
cancer have used overall death, which is inappropriate when
studying the effect of certain exposures on breast cancer survival.
Obese women are known to have a higher general mortality, mainly
because of cardiovascular causes (Lahmann et al, 2002; Adams et al,
2006). Among young breast cancer women, in whom the vast
majority of deaths are because of cancer, overall death can be a good
proxy, but for postmenopausal women, the influence from other
deaths are considerable and the association between obesity and
breast cancer-specific survival from such studies is obscured.
Therefore, despite the large number of earlier studies, we consider
that more studies assessing breast cancer-specific survival are
warranted. Another consideration is the method of diagnosis. Obese
compared with normal weight women, have larger breasts, which
makes palpation a less likely means of detection as reflected in large
non-screening detected tumours diagnosed in obese women (Hunt
and Sickles, 2000; Porter et al, 2006). On the other hand, obesity is
related to a lower mammographic breast density (Hunt and Sickles,
2000; Boyd et al, 2006), thereby might give an earlier diagnosis. Thus,
the association between obesity and breast cancer characteristics and
survival might depend on screening intensity. We found that obese
women not diagnosed by screening had larger tumours compared
with normal weight women, but we could not see this transferred to
poorer survival among obese compared with normal weight women.
Mammographic screening intensity influences the distribution
of the breast cancer characteristics and survival by earlier cancer
detection (Shen et al, 2005). If screening use differs between obese
and non-obese women, this might introduce a bias, neglected in
most earlier studies. In our study, as in another (Porter et al, 2006),
we did not find obesity to influence screening intensity.
Our findings of a poorer survival among obese compared with
normal weight HRT users are statistically significant, and therefore
possibility of chance is small. However, as the study is observa-
tional, other factors may be responsible, such as better health, less
patient’s or doctor’s delay, and possibly better treatment among
normal weight women. Treatment was considered, and was
similarly distributed among BMI groups.
Our main conclusion is that obesity does not seem to confer a
poor breast cancer-specific survival in never HRT users. The
worsened prognosis seen in postmenopausal obese breast cancer
patients is confined to HRT users. Tumours in normal weight HRT
users showed a less aggressive behaviour. The influence of BMI on
breast cancer survival was not explained by mode of detection.
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